Jiadao Capital backs Meyer FSMP in strategic move on China's medical nutrition sector

Meyer FSMP Hong Kong, a comprehensive solution provider and services company in oncology nutrition therapy, has completed a strategic financing round totaling tens of millions of RMB, exclusively funded by Jade Capital. Following this investment, Meyer FSMP will not only gain substantial financial support but will also leverage Jiadao Capital's extensive industrial footprint in the global health sector—particularly in areas such as Japanese Kampo medicine, food-medicine homologation, Foods for Special Medical Purposes (FSMP), and medically functional foods—to accelerate market expansion and further promote the clinical implementation of its oncology nutrition therapy solutions.

The global demand for Foods for Special Medical Purposes (FSMP) is experiencing rapid growth, driven by an aging population, rising prevalence of chronic diseases, metabolic disorders, and other health issues. Simultaneously, increasing health awareness and advancements in medical technology are further accelerating the development of the global FSMP market.

The Chinese FSMP industry is projected to potentially achieve a market scale of trillions of yuan in the future. However, the current penetration rate of FSMP in China stands at only 3%, significantly lower than the 40% seen in mature markets like Europe and the United States. This gap underscores the immense growth potential awaiting the Chinese FSMP market.

In response to long-standing challenges that have constrained the industry's development, Meyer FSMP has, through years of practical experience, effectively established an integrated solution for standardizing nutritional therapy diagnosis and treatment systems. The company has successfully collaborated with dozens of hospitals in recent years to implement this integrated solution for standardizing nutritional therapy systems, achieving the desired outcomes.

As industry associations highlighted at the end of 2024, 2025 will mark the inaugural year of the "Nutrition Co-construction Initiative"—an endeavor in which Meyer FSMP has already been deeply engaged for some time.

Meyer FSMP primarily focuses on nutritional therapy for oncology, geriatric care, ERAS (Enhanced Recovery After Surgery), and ICU patients. The company has currently obtained product registration certifications for two FSMP products: a Carbohydrate Component Formula Food for Special Medical Purposes and a Full Nutritional Formula Food for Special Medical Purposes. Additionally, ten other FSMP products, including protein components, short-peptide full nutrition, thickening components, and oncology-specific full nutrition, are under development and registration.

With the completion of this funding round, Meyer FSMP will further expand into the Hong Kong market, using it as a strategic hub to radiate into Middle Eastern regions such as the UAE. Simultaneously, leveraging the unique advantages of its investor, Jiadao Capital, in the health and wellness sector, Meyer FSMP will capitalize on this partnership to jointly advance market education and cultivate consumer demand for products that integrate "Traditional Wisdom + Scientific Nutrition." This collaboration aims to meet consumers' diverse and precise health needs, releasing a synergistic "1+1>2" multiplier effect to accelerate market expansion.